Sectors:
Locations:
Min Investment:
Max Investment:
Target Investment:
2020
APIM Therapeutics AS is a venture-capital financed biotech spin-off from the Norwegian University of Science and Technology (NTNU, Trondheim). The company is developing a first-in-class drug candidate, ATX-101, for several oncology indications. ATX-101 targets a novel, stress-related therapeutic intervention point, and is currently undergoing phase 2 clinical testing.
2007
2007
With offices across Europe, United States and Asia and with a multi-disciplinary Partner team, Ventac Partners offer hands-on experience and skills required to drive innovative technology-based projects from the laboratory to the market in the fields of Biotech, Pharma and Medtech. Over the last 15 years, Ventac Partners has experienced a steadily growing business with industry and academic institutions, and has founded, incorporated and exited several companies together with our partners and investors and consulted on hundreds of different early stage or advanced projects. Within Ventac Partners, I have co-founded and/or am/were involved in several portfolio companies in various advisory and operational roles. Among different roles undertaken, I have been serving as the CEO of APIM Therapeutics, a biotech company with a phase 2 asset in oncology, for several years (see also separate affiliation, expanded as of Jan. 2020). I have also served as the Head of Preclinical R&D of Avexxin AS (currently Coegin Pharma). I am/was also actively engaged in a variety of additional technology search and evaluation activities in various technological and product fields.
2010
2010
Gerolymatos International (GI) specializes in the development and commercialization of proprietary OTC, medical device and cosmetic products in more than 50 countries globally. These include a series of nasal and auricular medical devices based on GI's global brand, Sinomarin® and the cosmetic hair care line, Foltene®. Within GI, I advise the company on R&D activities, global registration, medical and scientific affairs.
2021
Providing strategic input and advice to the company and its management being a member of their Advisory Board.
2015 - 2016
2015 - 2016
Foltene Laboratories Srl specializes in the development and commercialization of cosmetic products in the hair care, eyebrow, eyelash and nail categories. Foltene® products are currently being sold in more than 20 countries worldwide. Advising the company on various technological aspects, my main role focused on the development of improved Foltene® products for various uses.
2007 - 2014
2007 - 2014
The Hellenic Bio Cluster (HBio) is a coalition of Greek Life Sciences companies, encompassing corporate players in the sectors of Biotechnology, Diagnostics, Medical Devices, Pharmaceuticals and Services. HBio aims to promote the Greek Life Science business sector and facilitate business & research collaborations between Greek and foreign companies and research groups.
2002 - 2010
2002 - 2010
Identification, licensing and development of novel therapeutic and diagnostic candidate products in the field of oncology.
2006 - 2008
2006 - 2008
Management of pharmaceutical R & D activities in the fields of wound healing & inflammation; co-ordination of medical device and cosmetic product development; business development & licensing of pharma & OTC products
2000 - 2002
2000 - 2002
Development of novel therapeutics (biologicals) in the fields of oncology and inflammation; development and commercialization of molecular biology reagents for Life Science Research & Development
1999 - 2001
1999 - 2001
Preclinical translational research in the field of molecular oncology and carcinogenesis.